Prathibha Mohan

Ms. Prathibha Mohan

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Cell
Verified
Journal Article
Closed access
VSViraj R. Sanghvi
Viraj R. Sanghvi
JLJosef Leibold
Josef Leibold
MMMarco Mina
Marco Mina
PMPrathibha Mohan
Prathibha Mohan
MBMarjan Berishaj
Marjan Berishaj
HWHans-Guido Wendel
Hans-Guido Wendel

22 June 2020 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
SPSara Parsa
Sara Parsa
AOAna Ortega-Molina
Ana Ortega-Molina
HYHsia-Yuan Ying
Hsia-Yuan Ying
MJMan Jiang
Man Jiang
MTMatt Teater
Matt Teater
HWHans-Guido Wendel
Hans-Guido Wendel

25 February 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
KSKamini Singh
Kamini Singh
JLJianan Lin
Jianan Lin
NLNicolas Lecomte
Nicolas Lecomte
PMPrathibha Mohan
Prathibha Mohan
AGAskan Gokce
Askan Gokce
HWHans-Guido Wendel
Hans-Guido Wendel
Pancreatic adenocarcinoma (PDAC) epitomizes a deadly cancer driven by abnormal KRAS signaling. Here, we show that the eIF4A RNA helicase is required for translation of key KRAS signaling molecules and that pharmacological inhibition of eIF4A has single-agent activity against murine and human PDAC models at safe dose levels. EIF4A was uniquely required for the translation of mRNAs with long and highly structured 5′ untranslated regions, including those with multiple G-quadruplex elements. Computational analyses identified these features in mRNAs encoding KRAS and key downstream molecules. Transcriptome-scale ribosome footprinting accurately identified eIF4A-dependent mRNAs in PDAC, including critical KRAS signaling molecules such as PI3K, RALA, RAC2, MET, MYC, and YAP1. These findings contrast with a recent study that relied on an older method, polysome fractionation, and implicated redox-related genes as eIF4A clients. Together, our findings highlight the power of ribosome footprinting in conjunction with deep RNA sequencing in accurately decoding translational control mechanisms and define the therapeutic mechanism of eIF4A inhibitors in PDAC.Significance: These findings document the coordinate, eIF4A-dependent translation of RAS-related oncogenic signaling molecules and demonstrate therapeutic efficacy of eIF4A blockade in pancreatic adenocarcinoma.

29 May 2019 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
KSKamini Singh
Kamini Singh
JLJianan Lin
Jianan Lin
YZYi Zhong
Yi Zhong
ABAntonija Burčul
Antonija Burčul
PMPrathibha Mohan
Prathibha Mohan
HWHans-Guido Wendel
Hans-Guido Wendel
The oncogenic c-MYC (MYC) transcription factor has broad effects on gene expression and cell behavior. We show that MYC alters the efficiency and quality of mRNA translation into functional proteins. Specifically, MYC drives the translation of most protein components of the electron transport chain in lymphoma cells, and many of these effects are independent from proliferation. Specific interactions of MYC-sensitive RNA-binding proteins (e.g., SRSF1/RBM42) with 5′UTR sequence motifs mediate many of these changes. Moreover, we observe a striking shift in translation initiation site usage. For example, in low-MYC conditions, lymphoma cells initiate translation of the CD19 mRNA from a site in exon 5. This results in the truncation of all extracellular CD19 domains and facilitates escape from CD19-directed CAR-T cell therapy. Together, our findings reveal MYC effects on the translation of key metabolic enzymes and immune receptors in lymphoma cells.

18 November 2014 in Science Signaling
Verified
Journal Article
Closed access
PDF file
VSViraj R. Sanghvi
Viraj R. Sanghvi
KMKonstantinos J. Mavrakis
Konstantinos J. Mavrakis
JMJoni Van der Meulen
Joni Van der Meulen
MBMichael Boice
Michael Boice
AWAndrew L. Wolfe
Andrew L. Wolfe
HWHans-Guido Wendel
Hans-Guido Wendel
A set of microRNAs that target the Myb oncogene may function as tumor suppressors in T cell leukemia.

5 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
VSViraj Sanghvi
Viraj Sanghvi
PMPrathibha Mohan
Prathibha Mohan
KSKamini Singh
Kamini Singh
LCLinlin Cao
Linlin Cao
MBMarjan Berishaj
Marjan Berishaj
HWHans-Guido Wendel
Hans-Guido Wendel
Inhibition of the eIF4A RNA helicase with silvestrol and related compounds is emerging as a powerful anti-cancer strategy. We find that a synthetic silvestrol analogue (CR-1-31 B) has nanomolar activity across many cancer cell lines. It is especially active against aggressive MYC+/BCL2+ B cell lymphomas and this likely reflects the eIF4A-dependent translation of both MYC and BCL2. We performed a genome-wide CRISPR/Cas9 screen and identified mechanisms of resistance to this new class of therapeutics. We identify three negative NRF2 regulators (KEAP1, CUL3, CAND1) whose inactivation is sufficient to cause CR1-31-B resistance. NRF2 is known to alter the oxidation state of translation factors and cause a broad increase in protein production. We find that NRF2 activation particularly increases the translation of some eIF4A-dependent mRNAs and restores MYC and BCL2 production. We know that NRF2 functions depend on removal of sugar adducts by the frutosamine-3-kinase (FN3K). Accordingly, loss of FN3K results in NRF2 hyper-glycation and inactivation and resensitizes cancer cells to eIF4A inhibition. Together, our findings implicate NRF2 in the translation of eIF4A-dependent mRNAs and point to FN3K inhibition as a new strategy to block NRF2 functions in cancer.